Key result
CYP2B6 slow metabolizer status in patients receiving methadone was associated with an increased risk of prolonged QTc (OR 4.5; 95% CI 1.2-17.7; P=0.03).
Why the study?
Does CYP2B6 slow metabolizer status increase the risk of QT interval prolongation in patients receiving methadone?
Population
179 patients receiving-methadone, alongside in vitro whole-cell patch-clamp experiments using cells…
Comparison
CYP2B6 slow metabolizer (*6/*6) genotype vs CYP2B6 extensive metabolizer (non *6/*6) genotype
Design
Cross-sectional
Authors
Loading...
May warrant enhanced QTc monitoring in CYP2B6 slow metabolizers on methadone; hypothesis-generating for genotype-guided alternatives.
Observational (n=179)
Does CYP2B6 slow metabolizer status increase the risk of QT interval prolongation in patients receiving methadone?
Odds Ratio: 4.5 (95% CI 1.2–17.7)
p-value: p=0.03
CYP2B6 slow metabolizer status increases the risk of methadone-induced QT prolongation due to reduced clearance of the more potent hERG blocker (S)-methadone, suggesting (R)-methadone may be a safer alternative.
Eap et al. (2007) conducted an observational in Patients receiving (R,S)-methadone (n=179). CYP2B6 slow metabolizer (*6/*6) genotype vs. Extensive metabolizers (non *6/*6 genotype) was evaluated on Prolonged QTc (OR 4.5, 95% CI 1.2-17.7, p=0.03). CYP2B6 slow metabolizer status in patients receiving methadone was associated with an increased risk of prolonged QTc (OR 4.5; 95% CI 1.2-17.7; P=0.03).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: